Abstract. Netrin-1 (NTN1) has been demonstrated to promote tumorigenesis in multiple types of cancer; however, its role in the growth of gastric cancer (GC) cells has not been described in detail. In the present study, the data suggested that NTN1 knockdown significantly decreased the proliferation of GC cells, whereas NTN1 overexpression had an opposing effect. Furthermore, the use of focal adhesion kinase (FAK) inhibitor decreased the proliferation of GC cells. It was also revealed that NTN1 markedly induced the phosphorylation of FAK, extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK), but did not induce the phosphorylation of P38. In addition, the expression of ERK and JNK was markedly inhibited by treatment with FAK inhibitor. Xenograft analysis using GC cells revealed that NTN1 overexpression promoted tumor growth. Furthermore, the expression of NTN1 in samples collected from nude mice was downregulated in the NTN1 knockdown group and upregulated in the NTN1 overexpression group compared with the control short hairpin RNA group. These results suggest that NTN1-induced GC cell proliferation is mediated by activating ERK/MAPK signaling cascades via the distinct activation of FAK.

Introduction

Gastric cancer (GC), the fourth most common type of cancer, has been demonstrated to be the third leading cause of cancer-associated mortality in males and the fifth leading cause of cancer-associated mortality in females worldwide (1). In order to develop an effective treatment for GC, the molecular mechanisms of its development and progression must be elucidated. However, in the past decade, limited progress has occurred in studying the progression of GC.

Netrin-1 (NTN1) is a laminin-like protein that was initially identified as one of the axonal guidance molecules in neuronal cell development (2). NTN1 has several dependent receptors, including uncoordinated-5-homolog (UNC5H), which consists of UNC5H1, UNC5H2, UNC5H3 and UNC5H4, deleted in colorectal cancer (DCC), neogenin and Down syndrome cell adhesion molecule. Previous studies have demonstrated that NTN1 mRNA and protein expression is associated with numerous types of cancer, including colorectal (3,4), hepatic (5), neuroblastoma (6), breast (7), pancreatic (8,9), prostate (10) and non-small cell lung cancer (11). In addition, NTN1 has been demonstrated to regulate cancer cell proliferation, migration, invasion and apoptosis (5,8,9,12,13). Our previous study revealed that NTN1 promoted GC cells growth via its receptor neogenin (14); however, the downstream signaling pathway remains to be elucidated.

Numerous studies have reported that focal adhesion kinase (FAK) may be one of the primary downstream effector molecules of NTN1 in neural system development (2). NTN1 has several dependent receptors, including uncoordinated-5-homolog (UNC5H), which consists of UNC5H1, UNC5H2, UNC5H3 and UNC5H4, deleted in colorectal cancer (DCC), neogenin and Down syndrome cell adhesion molecule. Previous studies have demonstrated that NTN1 mRNA and protein expression is associated with numerous types of cancer, including colorectal (3,4), hepatic (5), neuroblastoma (6), breast (7), pancreatic (8,9), prostate (10) and non-small cell lung cancer (11). In addition, NTN1 has been demonstrated to regulate cancer cell proliferation, migration, invasion and apoptosis (5,8,9,12,13). Our previous study revealed that NTN1 promoted GC cells growth via its receptor neogenin (14); however, the downstream signaling pathway remains to be elucidated.

In the present study, the role of NTN1 in promoting the growth of GC cells and its associated signaling pathways...
was investigated. It was demonstrated that NTN1 significantly promoted GC cells proliferation in vitro and in vivo. Furthermore, the present results suggest that NTN1-induced GC cells proliferation was mediated by the ERK/MAPK signaling pathway via activation of FAK.

Materials and methods

Cell culture and reagents. The human GC cell lines (SGC7901 and MGC803) were obtained from the Cell Bank of the Chinese Academy of Medical Science (Shanghai, China). All cell lines were cultured in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37°C in an atmosphere containing 5% CO2. MEK inhibitor U0126 and FAK inhibitor PF562271 (Invitrogen; Thermo Fisher Scientific, Inc.) were cultured in RPMI-1640 (Gibco; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. cDNA was produced from RNA by RT using a PrimeScript RT reagent kit (Takara Biotechnology Co., Ltd., Dalian, China). The RT temperature protocol used was as follows: 15 min at 37°C; reverse transcriptase inactivation for 5 sec at 85°C; followed by storage at 4°C. The primer sequences were as follows: 5'-AGATCTCTGACCGAGCGTG GC-3' and reverse, 5'-CCAGGGAGAAGAGGATGCG-3'; NTN1 forward, 5'-AAGCAGGGCAACAGTCGTAT-3' and reverse, 5'-TGCTCTTGCTGCCCAGGTG-3'; qPCR was performed using SYBR Green Real-time PCR Master Mix (Roche Diagnostics GmbH, Mannheim, Germany). Briefly, the qPCR was performed on an Applied Biosystems 7500 Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermal profile: Hot-start DNA polymerase activation to 95°C for 10 min; 40 cycles of 95°C for 15 sec and 60°C for 1 min; followed by melt curve analysis at 95°C for 15 sec, 60°C for 1 min and 95°C for 15 sec. Relative expression of NTN1 mRNA in tissues was analyzed according to the 2-ΔΔCt method (20). β-actin used as an internal control gene.

Western blot analysis. SGC7901 and MGC803 cells were harvested for protein extraction according to standard procedures. Cell extracts were prepared for western blotting using a Total Protein Extraction kit (cat. no. KGP2100; Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). Subsequently, a BCA protein assay was used for protein quantification. A total of 40 µg of protein extracts from each group were resolved using 10% SDS-PAGE and transferred to polyvinylidene fluoride membranes. Following blocking with 5% skimmed milk at room temperature for 2 h, the membranes were incubated with specific primary antibodies in dilution buffer at 4°C overnight. The following primary antibodies were used: NTN1 (cat. no. ab126729; anti-rabbit; 1:200 dilution; Abcam, Cambridge, UK), GAPDH (cat. no. 51332; anti-mouse), phosphorylated (p)-FAK (cat. no. 3284; anti-rabbit), FAK (cat. no. 13009; anti-rabbit), p-c-Jun N-terminal kinase (JNK) (cat. no. 4668; anti-rabbit), JNK (cat. no. 9252; anti-rabbit), p-ERK (cat. no. 4376; anti-rabbit), ERK (cat. no. 4695; anti-rabbit), p-P38 (cat. no. 4631; anti-rabbit) and P38 (cat. no. 8690; anti-rabbit) (all 1:1,000 dilution; all from Cell Signaling Technology, Inc., Danvers, MA, USA). GAPDH was used as an internal control. Following this, the membranes were washed 3 times with TBS-Tween-20 and incubated with horseradish peroxidase (HRP)-conjugated anti-mouse (cat. no., GAM007; 1:1,000 dilution) or anti-rabbit IgG (cat. no. GAB007; 1:1,000 dilution) (both from Hangzhou Multi Sciences Biotech Co., Ltd., Hangzhou, China) at room temperature for 2 h. Bands were visualized using ECL Plus (EMD Millipore, Billerica, MA, USA) with a FluorChem E enhanced chemiluminescence detection system (ProteinSimple, San Jose, CA, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated from tumor xenograft tissues using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) following the manufacturer's protocol. cDNA was produced from RNA by RT using a PrimeScript RT reagent kit (Takara Biotechnology Co., Ltd., Dalian, China). The RT temperature protocol used was as follows: 15 min at 37°C; reverse transcriptase inactivation for 5 sec at 85°C; followed by storage at 4°C. The primer sequences were as follows: 5'-AGATCTCTGACCGAGCGTG GC-3' and reverse, 5'-CCAGGGAGAAGAGGATGCG-3'; NTN1 forward, 5'-AAGCAGGGCAACAGTCGTAT-3' and reverse, 5'-TGCTCTTGCTGCCCAGGTG-3'; pPCR was performed using SYBR Green Real-time PCR Master Mix (Roche Diagnostics GmbH, Mannheim, Germany). Briefly, the qPCR was performed on an Applied Biosystems 7500 Fast Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermal profile: Hot-start DNA polymerase activation to 95°C for 10 min; 40 cycles of 95°C for 15 sec and 60°C for 1 min; followed by melt curve analysis at 95°C for 15 sec, 60°C for 1 min and 95°C for 15 sec. Relative expression of NTN1 mRNA in tissues was analyzed according to the 2-ΔΔCt method (20). β-actin used as an internal control gene.

Tumor xenograft with human GC cells in nude mice. A total of 15, 4-week-old male nude BALB/c mice (weight range, 13-15 g) were purchased from the Department of Laboratory Animal Centre of Yangzhou University (Yangzhou, China) and divided into 3 groups at random. All mice were raised following the approved Institutional Animal Care Procedure and performed according to the protocols approved by the Shanghai Jiao Tong University Medical School Animal Care Committee.
under pathogen-free conditions, including at room temperature (21-26°C) and 12 h light/dark cycle. The mice received 150 ml water and 5 g food per 100 g body weight per day. SGC7901 and MGC803 cells (NTN1 knockdown, control and NTN1 overexpression) were implanted into the right flank of the nude mice by subcutaneous injection (2x10⁵ cells in 100 μl of PBS) to promote tumor formation. Bidimensional tumor diameters were measured using a slide caliper every 7 days. Nude mice were euthanized after 4 weeks. Xenograft tumor volume was calculated using the following formula: (ab)² x (0.5)², whereby a represents the length of the tumor and b represents the width diameter of the tumor (21). The present study was approved by the Jiangsu University Animal Ethics Committee (Zhenjiang, China).

**Immunohistochemical staining (IHC).** Xenograft tumor samples were fixed in 4% formalin at room temperature overnight and embedded in paraffin. Then, the sections were washed in PBS 3 times and blocked in 5% bovine serum albumin (Servicebio Technology Co., Ltd., Wuhan, China) for 30 min at room temperature. The 4-μm slices were incubated with ki-67 antibody (cat. no. ab15580; anti-rabbit; 1:100 dilution; Abcam) at 4˚C overnight and washed with PBS 3 times. Following incubation with HRP-polymer-conjugated secondary antibody (cat. no. ab6721; goat anti-rabbit; 1:1,000 dilution; Abcam) at room temperature for 1 h, the slices were dyed with diaminobenzidine solution for 3 min at room temperature and then stained with 0.2% hematoxylin at room temperature for 3 min. The sections were observed with an inverted microscope (original magnification, x100; NIKON ECLIPSE TI-SR; Nikon Corporation, Tokyo, Japan). Ki-67 expression levels were evaluated according to the percentage of positively stained tumor cells and cell staining intensity. The staining intensity was graded as follows: 0 (no staining); 1 (weak); 2 (moderate); and 3 (strong). The following scores were used to describe the overall proportion of Ki-67 positive cells: 0 (negative); 1 (<30%); 2 (30-60%); and 3 (>60%). The two scores were multiplied, with scores ≥4 being defined as high expression, and scores <4 as low expression.

**Statistical analysis.** Statistical analysis was performed using SPSS software (version 22; IBM, Corp., Armonk, NY, USA). Data are presented as the mean ± standard error of the mean. Differences between 2 groups were evaluated using paired student t-tests. Data from >2 groups were compared with two-way analysis of variance followed by a least-significant difference post hoc test. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**NTN1 enhances GC cells proliferation in vitro.** To investigate the role of NTN1 on GC cells proliferation, MGC803 and SGC7901 cells were transfected with lentivirus to overexpress or knock down NTN1. As shown in Fig. 1A, NTN1 protein expression was markedly decreased following silencing and increased following overexpression, indicating that transfection was successful. CCK-8 results revealed that NTN1 silencing significantly decreased the proliferation of GC cells compared with the control group. By contrast, NTN1 overexpression notably enhanced cell proliferation in MGC803 and SGC7901 cells (Fig. 1B and C). To further explore the mechanism responsible for the NTN1-induced GC growth, the cell cycle distribution in each group was investigated using FCM. Similarly, NTN1 knockdown in MGC803 and SGC7901 cells significantly increased the percentage of cells in G0/G1 phase, whereas the opposite was observed in NTN1-overexpressed cells (Fig. 1D and E). Taken together, these results suggest that NTN1 overexpression promoted GC cells proliferation, while NTN1 knockdown induced cell cycle arrest at the G0/G1 phases.

**Enhanced GC cell proliferation induced by NTN1 is FAK dependent.** The effect of NTN1 on the phosphorylation of FAK, which is considered to be essential in netrin signaling pathways (16,22), was examined. The results indicated that PF562271, a FAK inhibitor, markedly suppressed FAK phosphorylation in MGC803 and SGC7901 cell lines (Fig. 2A). The results also demonstrated that the proliferation of GC cells pretreated with PF562271 was significantly inhibited (Fig. 2B and C). In order to demonstrate that NTN1-induced GC cells growth was mediated by FAK, FCM was used to assess the distribution of GC cells in the cell cycle following NTN1 knockdown and overexpression. As shown in Fig. 2D and E, PF56227 significantly increased the percentage of cells in the G0/G1 phases in MGC803 and SGC7901 cells.

**Effects of NTN1 on the ERK/MAPK signaling pathway.** The ERK/MAPK signaling pathway is the primary downstream pathway of FAK (22). Whether ERK/MAPK signal cascades participate in NTN1-enhanced GC cell proliferation was investigated. It was demonstrated that FAK, ERK and JNK phosphorylation were reduced in MGC803 and SGC7901 cells following NTN1 knockdown compared with the negative control group. By contrast, increased phosphorylation of FAK, ERK and JNK was observed in the NTN1 overexpression group, while no changes were detected in the total protein levels (Fig. 3A). However, another downstream target of MAPK signaling pathway, P38, was not significantly altered in GC cells following NTN1 knockdown and overexpression. To verify the role of NTN1 in signaling pathways mediated by FAK, MGC803 and SGC7901 cells with NTN1 overexpression were treated with PF56227 for 24 h. The results revealed that PF56227 significantly inhibited NTN1-induced phosphorylation of ERK and JNK (Fig. 3B).

**Effects of ERK on GC cells proliferation ability in vitro.** The effect of ERK on GC cell proliferation was analyzed. ERK phosphorylation was suppressed in MGC803 and SGC7901 cell lines following treatment with MEK inhibitor U0126 (Fig. 4A). The results demonstrated that pretreatment with the MEK inhibitor (U0126) also downregulated GC cell proliferation (Fig. 4B and C) and increased the percentage of cells in the G0/G1 phases (Fig. 4D and E). Taken together, these results demonstrated that the ERK/MAPK signaling pathway may be involved in enhancing GC cell proliferation and that NTN1 exerted this effect through the activation of FAK.

**NTN1 promotes tumor growth in nude mice inoculated with GC cells.** In order to investigate the effect of NTN1 on tumor
Figure 1. Effect of NTN1 on gastric cancer cell proliferation. (A) NTN1 was efficiently decreased following transfection with NTN1 knockdown lentivirus in MGC803 and SGC7901 cells. NTN1 was increased following transfection with NTN1 overexpression lentivirus. NTN1 expression was examined by western blot analysis following transfection for 48 h. The Cell Counting Kit-8 assay indicated that NTN1 knockdown suppressed the proliferation abilities of (B) MGC803 and (C) SGC7901 cells. (D) The effect of NTN1 on the GC cell cycle distribution was analyzed using flow cytometry and (E) quantified. *P<0.05, **P<0.01 and ***P<0.001. NTN1, Netrin-1; sh, shRNA; CTL, control.
Figure 2. Effects of NTN1 on the activation of FAK in vitro. (A) Western blot analysis was used to analyze the expression of FAK in MGC803 and SGC7901 cells pretreated with FAK inhibitor (PF562271). The Cell Counting Kit-8 assay indicated that the FAK inhibitor (PF562271) decreased the proliferation ability of (B) MGC803 and (C) SGC7901 cells transfected with lentivirus. A cell cycle assay was (D) performed and (E) quantified, which indicated that FAK inhibitor (PF562271) increased the percentage of cells in G0/G1 phase in MGC803 and SGC7901 cells. *P<0.05, **P<0.01 and ***P<0.001. FAK, focal adhesion kinase; NTN1, Netrin-1; sh, shRNA; CTL, control; p, phosphorylated.
Figure 3. Effects of NTN1 on the ERK/MAPK signaling pathway are dependent on FAK. (A) MGC803 and SGC7901 cells were transfected with NTN1 knockdown or overexpression lentivirus, and the expression levels of p-FAK/FAK, p-ERK/ERK, p-JNK/JNK and p-P38/P38 were analyzed using western blot analysis. (B) Western blot analysis revealed that pretreatment with FAK inhibitor (PF562271) altered the expression levels of p-ERK/ERK and p-JNK/JNK. FAK, focal adhesion kinase; NTN1, Netrin-1; sh, shRNA; CTL, control; p, phosphorylated; JNK, JUN N-terminal kinase; ERK, extracellular signal-regulated kinase.

Figure 4. Effect of ERK on gastric cancer cell proliferation in vitro. (A) Western blot analysis was used to analyze the expression of ERK in MGC803 and SGC7901 cells pretreated with MEK inhibitor (U0126). The proliferation abilities of (B) MGC803 and (C) SGC7901 cells pretreated with MEK inhibitor (U0126) were determined using a Cell Counting Kit-8 assay. Cell cycle analysis was (D) performed and (E) quantified, which indicated that the MEK inhibitor (U0126) increased the percentage of cells in G0/G1 phase in MGC803 and SGC7901 cells. *P<0.05 and **P<0.01. sh, shRNA; CTL, control; p, phosphorylated; ERK, extracellular signal-regulated kinase.
growth in nude mice, GC cells (NTN1 knockdown, control and NTN1 overexpression) were injected into the right flank of nude mice. As shown in Fig. 5A-F, the tumor volume and weight in the NTN1 knockdown group were decreased compared with the control group. Conversely, the tumor volume and weight in the NTN1 overexpression group were increased compared with the control group. Furthermore, the relative expression of NTN1 in samples collected from nude mice was measured using RT-qPCR. As shown in Fig. 5G and H, the expression of NTN1 was downregulated in the NTN1 knockdown group, while it was upregulated in the NTN1 overexpression group. Ki-67 IHC analysis was performed to assess GC cell proliferation in vivo. The positive nuclei rate of Ki-67 was lower in the NTN1 knockdown group and higher in NTN1 overexpression group (Fig. 5I and J). Taken together, these results indicate...
that proliferation ability of GC cells was impaired following NTN1 knockdown, which was consistent with the experimental results in vitro.

Discussion

The proto-oncogene NTN1 has been reported to promote cancer cell proliferation during tumor development (7,8,23). In the present study, the in vivo and in vitro results identified that the nerve-derived molecule NTN1 has the ability to stimulate GC cell proliferation, suggesting that NTN1 has an oncogenic effect. Furthermore, it was revealed that NTN1 induces the distinct activation of FAK, subsequently leading to the induction of the ERK/MAPK signaling pathway.

FAK is a cytoplasmic protein tyrosine kinase, which has been demonstrated to be involved in cell proliferation, including cell proliferation and migration (24). Previous studies have reported that FAK may be one of the primary downstream effectors of NTN1, functioning through the receptors DCC and neogenin (15,16). Furthermore, it has been reported that NTN1-induced cell proliferation and migration is mediated by the activation of FAK (17,25). The results of the present study suggest that FAK phosphorylation was decreased following NTN1 knockdown in GC cells, whereas NTN1 overexpression had the opposite effect. GC cell proliferation was significantly inhibited following pretreatment with FAK inhibitor, which is consistent with previous results (26,27). These results indicate that dysfunction of FAK signaling pathway may be an important mechanism involved in GC cell proliferation.

The ERK/MAPK signaling pathway has been demonstrated to serve important roles in the proliferation of various cells (28). In addition, the results of the present study revealed that ERK and JNK phosphorylation levels were increased following NTN1 overexpression, which has been confirmed to be a downstream effect of NTN1 in other studies (5,18). Notably, the mechanism by which NTN1 induces renal proximal tubular epithelial cells proliferation has been proposed as stimulation of the UNC5B, which triggers the activation of the ERK/MAPK signaling pathway (18). The results in the current study indicated that NTN1 knockdown decreased the phosphorylation of ERK and JNK, while P38 phosphorylation was unchanged. Furthermore, the present results suggest that the addition of the MEK inhibitor suppressed the proliferation ability of NTN1 in GC cells. However, it has been reported that NTN1 stimulates p38/MAPK, but not ERK/MAPK signaling pathways in Schwann cells (29). Notably, it was also reported that NTN1 suppressed the growth of pancreatic cancer via inhibition of the ERK/MAPK signaling pathway through its receptor UNC5B (30). In addition, NTN1 has been demonstrated to induce the inhibition of the ERK/MAPK signaling pathway during lung branching morphogenesis (31). These findings suggest that NTN1 possibly has bidirectional effects on the ERK/MAPK signaling pathway depending on the receptor types or ligand structure.

In conclusion, the present study demonstrated that the NTN1-induced promotion of GC cell proliferation was mediated via activation of the FAK/ERK/MAPK signaling pathway in vivo and in vitro. Considering the role of NTN1 on GC progression, the therapeutic potential of NTN1 in GC requires further investigation and evaluation.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Jiangsu Province Fund for ‘Six talent summits’ high-level talent (grant no. 2016-WSN-007) and Zhenjiang Key Research and Development Plan (grant nos. SH2015066 and SH2017023).

Availability of data and materials

All data generated or analyzed during this study are available upon reasonable request from the corresponding author.

Authors’ contributions

ZX and JC conceived and designed the study. KY, MS, YX and SD performed the experiments and acquired data. LW, JQ, LC and XF analyzed the data. KY drafted and edited the manuscript. All authors have given final approval of the version to be published.

Ethics approval and consent to participate

The present study was approved by the Jiangsu University Animal Ethics Committee.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

References


